Cyclooxygenase-2 expression in canine appendicular osteosarcomas

Journal of Veterinary Internal Medicine

Volumn 18, Issue 6, 2004, Pages 859-865

  Mullins, Marie N ^a,c   Lana, Susan E ^a   Dernell, William S ^a   Ogilvie, Gregory K ^b   Withrow, Stephen J ^a   Ehrhart, E J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Angel Care Cancer Center   (United States)

^c Animal Cancer Center   (United States)

Author keywords

Dog; Immunohistochemistry; Nonsteroidal anti inflammatory drugs (NSAIDs); Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2;

APOPTOSIS; ARTICLE; BONE TUMOR; DOG; MESENCHYME CELL; NONHUMAN; OSTEOSARCOMA; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BONE NEOPLASMS; COLORADO; CYCLOOXYGENASE 2; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SURVIVAL ANALYSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 11444261461     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<859:CEICAO>2.0.CO;2     Document Type: Article

References (38)

1. Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: Withrow SJ, McEwen EG, eds. Small Animal Clinical Oncology. Philadelphia, PA: WB Saunders; 2001:378-401.
2. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma, dog versus man. Clin Orthop Related Res 1991;270:159-167.
3. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-999.
4. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for the treatment of canine osteosarcoma. J Vet Intern Med 1991;5:205-210.
5. Berg J, Weinstein MJ, Springfield DS, Rand WM. Response of osteosarcoma in the dog to surgery and chemotherapy with doxorubicin. J Am Vet Med Assoc 1995;206:119-124.
6. Chun R, Kurzman ID, Couto G, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: Preliminary findings. J Vet Intern Med 2000; 14: 495-498.
7. Williams CS, Mann M, DuBois RN. The role of cyclooxygenase in inflammation, cancer, and development. Oncogene 1999;18:7908-7916.
8. 2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2001;64:1-4.
9. Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 2002;11:1749-1764.
10. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
11. Knapp DW, Richardson RC, Bottoms DG, et al. Phase I trial of piroxicam in 62 dogs bearing naturally-occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
12. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
13. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
14. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-256.
15. Vidal S, Kovacs K, Bell D, et al. Cyclooxygenase-2 expression in human pituitary tumors. Cancer 2003;97:2814-2821.
16. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-2645.
17. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-5650.
18. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-455.
19. Shono T, Tofilon TJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001;61:4375-4381.
20. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-434.
21. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418.
22. Kham KN, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2001;61:478-481.
23. Dore M, Lanthier I, Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 2003;40:207-212.
24. McEntee MF, Cates JM, Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol 2002;39:428-436.
25. Tremblay C, Dore M, Bochsler PN, Sirois J. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J Natl Cancer Inst 1999;91:1398-1403.
26. Khan KM, Stanfield KM, Trajkovic D, Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 2001;38:116-119.
27. Pestilli de Almeida EM, Piche C, Sirois J, Dore M. Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001;49:867-875.
28. Dickens DS, Kozielski R, Khan J, et al. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 2002;5:356-364.
29. Burry RW. Specificity controls for immunocytochemical methods. J Histochem Cytochem 2000;48:163-165.
30. Sabino MC, Ghilardi JR, Jongen JLM, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002;62:7343-7349.
31. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med 2001;110:43-45.
32. Moalic S, Liagre B, Le Bail JC, Beneytout JL. Dose dependant modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 2001;18:533-540.
33. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987.
34. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
35. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-1257.
36. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-328.
37. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005.
38. Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol 2003;55:16-20.